BIOPHARMAWIRE  |  RESOURCE LIBRARY  |  INVESTOR KITS

Biotech Pitch Deck Template

An investor-ready slide structure for Series A and B biotech fundraises — what to include, in what order, and why

Updated Q4 2025  |  BioPharmaWire Editors

A biotech pitch deck is not a science presentation. It is a fundraising document whose job is to convince a sophisticated investor to spend the next three weeks doing diligence on your company. Every slide has a job. Every word competes for attention. This template covers the 14 slides that institutional biotech investors expect to see, in the order they expect to see them, with guidance on what each slide needs to achieve and the most common mistakes founders make on each one.

The structure below applies to Series A and Series B raises for clinical-stage or late pre-clinical biotech companies. Adjust the depth and emphasis based on your stage — earlier stage companies will have less clinical data but should follow the same slide order.

The 14-Slide Structure

Slide 1:  Cover

Include: company name, one-sentence description of what you do, the raise (amount and series), and the date. The one-sentence description is harder than it looks. It should name the modality, the target or mechanism, and the indication. ‘A clinical-stage biotech developing a selective KRAS G12C inhibitor for patients with non-small cell lung cancer’ is a one-sentence description. ‘An innovative platform company advancing the next generation of precision oncology solutions’ is not.

Investor coaching:  Investors decide in the first 30 seconds whether to read on. The cover slide sets the tone. If the one-liner does not convey what the drug is, what disease it treats, and what stage the company is at, the deck has already failed.

Slide 2:  The Problem / Unmet Need

Lead with the patient, not the market. Describe the disease, who it affects, and why current treatment is inadequate. Three anchor statistics work well: diagnosed patient population, a key clinical outcome metric (survival or response rate), and economic burden. The standard of care section should be specific — name the drugs, state their efficacy, and explain precisely where they fail. Investors read hundreds of decks and will know immediately if your characterisation of the standard of care is accurate.

Common mistake:  Do not open with ‘the global oncology market is $200 billion.’ Market size is a consequence of the problem, not the problem itself. Lead with the patient story, then anchor with data.

Slide 3:  Our Solution / Mechanism of Action

Introduce the drug and the mechanism of action. A clean diagram of the mechanism is worth more than a paragraph of explanation. On the right side of the slide, answer three questions in three short points: what is mechanistically novel about the approach, what is the evidence that the target is validated, and how does the compound’s profile differ from the nearest competitor. Avoid the phrase ‘best-in-class’ unless you have data that supports it.

Investor coaching:  The MOA slide is read by both generalists and scientists. The diagram should be simple enough for a generalist to follow; the text should satisfy a scientist’s need for specificity. If your mechanism is genuinely novel, say so plainly and cite the evidence.

Slide 4:  Nonclinical Data / Proof of Concept

Show one great piece of data, not four mediocre ones. The ideal figure is in vivo efficacy in a disease-relevant model, clearly labelled with species, model, dose, route, n, and statistical test. Accompany it with three callout boxes: the headline result in one sentence, why the model is relevant to human biology, and the limitations you acknowledge proactively. Intellectual honesty on limitations builds more credibility than pretending they do not exist.

Common mistake:  A single clean, well-controlled experiment with a modest but reproducible effect is more fundable than a dramatic result from a poorly designed study. Investors who do proper diligence will find the weaknesses — founders who identify them proactively are trusted more.

Slide 5:  Development Plan

A four-phase visual showing where you are and where this raise takes you. Phases typically run: IND-enabling, Phase 1 FIH, Phase 2 PoC, and Phase 3 or partnership. Each phase gets a timeline and the key milestones within it. Below the phase diagram, show the use of proceeds with specific dollar allocations for clinical operations, CMC, nonclinical work, and G&A. This slide must answer three questions: what does this raise fund, what milestone does it get you to, and why is that milestone the right one to de-risk the asset for the next financing?

Investor coaching:  The right ask is the amount needed to reach the next value-creating milestone with 6 months of runway cushion beyond it. Model what happens if the raise closes at 30% below target — if that scenario leaves insufficient runway to reach the milestone, the raise is undercapitalised.

Slide 6:  Clinical Strategy

Detail the Phase 1 design across six elements: patient population and inclusion criteria, starting dose rationale and escalation scheme, primary and secondary endpoints, site and CRO strategy, regulatory status (IND filed, designations obtained), and data readout timeline. Institutional investors at Series A review this slide with a clinical expert. The design must be internally consistent — the starting dose must follow from your nonclinical MABEL or NOAEL, the endpoints must follow from the mechanism, and the site selection must be credible for the indication.

Common mistake:  Inconsistencies in trial design kill deals in diligence. If the starting dose is not traceable to the nonclinical package, or if the endpoint is not aligned with the mechanism, sophisticated investors will find this. Align with FDA on trial design at the pre-IND meeting before finalising this slide.

Slide 7:  Competitive Landscape

A comparison table with your drug in one column and the two or three strongest competitors in adjacent columns. Rows should cover mechanism, development stage, biomarker requirement, route of administration, key efficacy metric, and your differentiation. Include the strongest competitors, not the weakest. The differentiation row is the most important — it must be specific, data-driven, and defensible. Source the table to ClinicalTrials.gov and published literature with a date.

Investor coaching:  Investors will build their own competitive table regardless. Yours should be pre-emptive and honest. A company that has done the competitive analysis well and presents it transparently inspires significantly more confidence than one that appears to minimise competitive risk.

Slide 8:  Intellectual Property

Cover four areas: composition of matter patent (the gold standard — protects the molecule itself), method of use patents, manufacturing or formulation patents if applicable, and trade secrets. For each granted or pending patent include the application or patent number, filing date, key jurisdictions, and expiry date before and after patent term extension. State clearly whether the IP is owned by the company or licensed from a university. If licensed, summarise the key terms: exclusivity, sublicense rights on acquisition, change of control provisions. Include a statement that a freedom-to-operate analysis has been conducted and when.

Common mistake:  Missing IP assignments from founders or early employees are a leading cause of deal failure in diligence. All founders, employees, and consultants must have signed IP assignment agreements confirming that work-product IP belongs to the company. Verify this before approaching investors.

Slide 9:  Team

Four to six people with photos or initials, title, and three specific credentials each. The credentials that matter most: prior IND filings, clinical trials led, companies exited, fundraises closed. Academic publications and degrees are supporting evidence, not primary credentials for an operations-focused role. Below the management team, list the Scientific Advisory Board members by name and institution, and the Board of Directors. The team slide is read before the science slides by most institutional investors. It is the most important slide in the deck.

Investor coaching:  The most fundable early-stage biotechs are not the ones with the most complete checklist — they are the ones where the science is compelling, the team is credible, and the founders understand their gaps without being defensive about them. Acknowledge any team gaps and state the plan to fill them.

Slide 10:  Market Opportunity

Build up from diagnosed patients, not down from total market size. Show the funnel: total diagnosed, eligible by indication criteria, biomarker-positive if applicable, addressable at launch. Every step must be sourced. Close the slide with the peak sales estimate built explicitly from patient population, penetration rate, price, and treatment duration. The penetration rate is the most scrutinised assumption — benchmark it against comparable approved drugs in the same indication, not against analyst consensus for the total market.

Common mistake:  Top-down market size figures from analyst reports (‘the oncology market will reach $370B by 2030’) are not credible to experienced investors. Build bottom-up from patients and price. The model will be wrong — investors assess the quality of the assumptions, not the precision of the number.

Slide 11:  Regulatory Strategy

Cover four areas: the regulatory pathway (NDA or BLA, FDA division, proposed indication text), FDA interactions to date (pre-IND meeting summary if held), expedited designations (Fast Track, BTD, ODD — held, sought, or planned with timeline), and the approval timeline from IND to projected US approval. If you have FDA designations, lead with them — they are meaningful signals that FDA has engaged with your development approach and found it credible. If you have not yet had a pre-IND meeting, state when it is planned.

Investor coaching:  Regulatory sophistication is diligenced carefully. A team that has already engaged FDA — even just with a pre-IND meeting — demonstrates operational maturity. Designations such as Fast Track, BTD, and ODD carry real financial and regulatory value and should be highlighted prominently.

Slide 12:  Milestones and Use of Proceeds

A milestone timeline showing what happens in each of the next three years, followed by a specific breakdown of how the capital raised will be deployed. Milestones should be specific and verifiable, not vague — not ‘Phase 1 data’ but ‘RP2D declaration with PK/PD data, Q3 2027.’ The use of proceeds breakdown should include a contingency line and state the number of months of runway the raise provides. End with the next financing trigger — the specific milestone that will position the company for Series B or a partnership.

Common mistake:  Milestones that cannot be verified (vague language, no dates, no specific endpoints) signal that management has not thought rigorously about the development plan. Investors who see ‘Phase 1 completion’ without a date or endpoint definition will ask why — and the answer is usually that the team does not yet have a clear picture of what Phase 1 completion means.

Slide 13:  The Ask

State the raise amount, the target close date, the instrument (typically Series A preferred equity), and whether you have a lead investor identified. Include the pre-money valuation anchored to recent comparable transactions at the same stage in the same therapeutic area — have three comparables ready. Show the current capital structure: shares outstanding fully diluted, option pool percentage, prior round details. Do not leave the valuation blank — it signals you have not thought it through.

Investor coaching:  Have three recent deal comparables at the same stage in the same therapeutic area available for the Q&A. Investors will ask how you arrived at the valuation. ‘We think the company is worth $X because of the science’ is not an answer. ‘Three recent Series A oncology programs with Phase 1 data raised at $80-120M pre-money, and we believe our differentiation warrants the top of that range’ is an answer.

Slide 14:  Closing Summary

Six reasons to back this company, one per bullet: science, team, regulatory, market, IP, and this raise. Each reason should be specific and backed by the evidence in the prior 13 slides. End with prominent contact information and the statement that a data room is available upon execution of an NDA. This is a call to action, not a recap of the deck.

Investor coaching:  The closing slide is the last thing investors see before they decide whether to take a next meeting. End strong. ‘First-in-class KRAS G12C inhibitor with 87% TGI in a validated model, led by a team that has previously filed 3 INDs and closed 2 Series A rounds, ODD obtained, $40M raise to Phase 1 RP2D’ is a closing statement. A list of generic bullet points is not.

Deck Mechanics: What Investors Notice

Length

14 slides in the body. Appendix slides covering additional data, financial model assumptions, and scientific detail are expected and appropriate — do not cram them into the main deck. A 20-slide main deck signals that the team cannot prioritise. A 10-slide deck signals that they are hiding something.

Format

Send as a PDF for initial outreach, not as a live PowerPoint. A PDF controls the experience and prevents formatting issues across devices. Keep file size under 10MB — large files do not open reliably on mobile. Use a clean, professional design: dark navy or white background, one accent colour, no clip art, no stock photography of scientists in lab coats.

Data room

Have a structured virtual data room ready before you start sending the deck. Investors who are interested will ask for it within days of receiving the deck. The data room should contain: the science package (full nonclinical data, IB if available), IP documentation (patents, FTO report, license agreement), corporate documents (cap table, incorporation documents, board minutes), team CVs, and the financial model. A well-organised data room signals that the team is ready for diligence.

Consistency

Every number in the deck must be consistent with the data room. Investors who proceed to diligence will verify every statistic. A patient prevalence figure that differs between the deck and the FDA ODD filing, or a patent expiry that differs between the deck and the patent documents, creates immediate questions about accuracy and attention to detail. Audit the deck against all source documents before sending.

Version control

Date every version of the deck. Do not send different versions with different content to different investors. If you update the deck during the fundraise (which is common as data comes in or as you refine the story based on investor feedback), update it consistently and note the version date on the cover.

What the Best Biotech Pitches Have in Common

Across the hundreds of biotech pitches that institutional investors evaluate each year, the ones that close consistently share five characteristics. First, the science is presented with intellectual honesty — the founders show the best data and acknowledge the limitations without being asked. Second, the team has done this before — at least one person on the founding team has previously navigated the specific challenge that lies immediately ahead (IND filing, Phase 1 design, regulatory engagement). Third, the competitive position is clear and data-driven — not ‘we are better’ but ‘here is specifically how the efficacy, safety, and patient selection data compares’. Fourth, the financial ask is sized to a specific milestone with a credible plan — not a round number with a vague use of proceeds. Fifth, the investors can see the exit — a clear view of who would want to own this asset at Phase 2 completion, at what premium, and based on what comparable transactions.

The deck is the invitation to the diligence process. It does not need to answer every question. It needs to make a sophisticated investor believe that the next three weeks of their time are worth spending on your company.

This template is an editorial product of BioPharmaWire reflecting common expectations among institutional life sciences investors as of Q4 2025. Individual investor preferences vary. It does not constitute financial, legal, or investment advice. Founders should engage experienced biotech counsel and financial advisors before approaching institutional capital.